Trust me, trust no one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good support bid!
A special message from @HarringtonKevin before he takes the stage with Psycheceutical CVO @zappyzapolin to open @microdosehq’s #WonderlandMiami! pic.twitter.com/9byUJluMP3
— Psycheceutical (@psycheceutical) November 3, 2022
Catch me on the main stage at Mana Wynwood tomorrow as I open the 2nd Annual @microdosehq #WonderlandMiami!
— Zappy Zapolin (@ZappyZapolin) November 2, 2022
It's going to be amazing - Tix link below!
Peace. Zappyhttps://t.co/5WWXv8ZTd0 pic.twitter.com/qSgQeUWHRk
It's an exciting week! Catch my latest interview with @TheDalesReport, where we talk about the massive movement happening in support of psychedelic research. Spoiler: it's a great time to get into the psychedelics market.
— Zappy Zapolin (@ZappyZapolin) November 1, 2022
Peace. Zappyhttps://t.co/Qzw1dnQLKd pic.twitter.com/3VdBUZWtk3
Hear from VP of Strategy and Communications, Kaia Roman (@kaiaromanauthor), on her experience working with psychedelic medicines and why she chose to join the Psycheceutical team. pic.twitter.com/2bJsAbaMTr
— Psycheceutical (@psycheceutical) October 31, 2022
Accumulating
Not according to due diligence. So there is that. Gap to profitability is closing as revenues trending up. They shed one location that was significantly underperforming and could not see a path forward. More locations coming.
Our patented NeuroDirect™ Topical Delivery System technology is designed to help patients receive the #mentalhealth benefits of psychedelic drugs, without unwanted side effects.
— Psycheceutical (@psycheceutical) October 27, 2022
Learn more at: https://t.co/zreeBPw6mU pic.twitter.com/p4CzPaZxp4
The company continues to trend upward, and new locations coming. Business is good moving towards profitability post pandemic challenges.
They still retain the gold standard in the board game cafe industry title. They have opportunity.
Regardless of how anyone feels about the management or current stock price, Snakes & Lattes continues on, building and growing and will be around for decades.
Facts
$FUNN
Holding steady, ready to run
I think evolution is faster than FINRA sheesh, get it done! We got a lot to do!
Snakes & Lattes Inc. Announces Nomination at Industry Prestigious Annual TAGIE Awards Alongside Disney, Hasbro and Barnes & Noble
Press Release | 10/25/2022
TORONTO, ON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Snakes & Lattes Inc. (OTC: FUNN) is proud to be in the running for ‘Most Innovative Retailer of the Year’ at the annual prestigious Toy and Game International Excellence ‘TAGIE’ awards. Winners will be revealed on November 19th.
The annual TAGIE awards held in Chicago are a significant industry showcase. There are 9 categories and many household names are in the lists of nominees. It is an honor to be a finalist in the ‘Most Innovative Retailer’ category along with other industry giants such as Disney (Star Wars), Barnes and Noble, F.A.O. Schwarz, and Hasbro Pulse.
Details of the event can be found at:
https://www.chitag.com/2022-tagie-awards-submissions
“Snakes & Lattes always had a special relation with the organizer of the TAGIE awards, Mary Couzin and her team at People of Play. 10 years ago, Mary invited me to speak at the awards and participate in panel discussions. She believed in us from early on and has been instrumental in our success. This gave us an incredible Tribune to present our concept to industry peers and created legitimacy as a member of the game industry. The network gained provides for numerous business opportunities and collaborations,” said Snakes & Lattes Inc. Founder, Ben Castanie.
Ben continued, “This is quite a big deal to be recognized by the industry at this level. Even nicer the recognition and nomination came from the public, it is a wonderful feeling of pride to be held side by side with the other big names.”
Previous winners of Innovative Retailers:
2021 LEGO
2020 Mastermind Toys
2019 Exploding Kittens
Event voting is open to the public until October 30th and can be found at:
https://www.peopleofplay.com/toy-game-innovation-awards/2022
Twitter update for awareness: We have migrated all followers to our twitter account @Snakesandlattes. Going forward this account will be used for corporate tweets. If you were already a follower, thank you! If you are not yet, please go on twitter and give us a follow!
See you at Snakes & Lattes!
About Snakes & Lattes Inc.
Snakes & Lattes Inc. currently operates 7 tabletop gaming bars and cafes: 3 located in Toronto, Ontario, Canada, 1 in Tempe, Arizona, 1 in Tucson, Arizona, 1 in Provo, Utah, and 1 in Chicago, Illinois. The company is in the process of expanding throughout North America. Snakes & Lattes Inc. was the first board game bar and cafe in North America, and is believed to be the largest in the world. Our board game cafes have the largest circulating public library of board games in North America for customers to choose from.
For more information on Snakes & Lattes Inc., please visit the website at:
www.snakesandlattes.com.
For further updates from Snakes & Lattes inc., please follow us on Twitter
@SnakesandLattes.
Safe Harbor Statement
This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company's OTC Market or Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should,", "will", "expect," "anticipate," "believe," "estimate," "confident," "intend," "plan" and other similar expressions. Our actual results, such as the Company's ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
Contact:
Ben Castanie
Snakes & Lattes Inc.
Telephone: (416) 500-2911
Email: ben@snakesandlattes.
Psychedelics are unlocking new ways to treat conditions like addiction and depression. Stream the latest episode of @novapbs on the PBS app. https://t.co/5QQ0QiiLwO
— PBS (@PBS) October 20, 2022
Dive into how our patented Janus particles technology is designed to allow the absorption of psychedelic drug compounds while bypassing side effects entirely.#psychedelicmedicine #psychedelicresearch #mentalhealth pic.twitter.com/sXtOIXEkKK
— Psycheceutical (@psycheceutical) October 19, 2022
As psychedelic medicine heads toward legalization, join me and @psycheceutical Chief Visionary Officer @ZappyZapolin as we open this year's @MicrodoseHQ #wonderlandmiami #psycheceuticals
— Kevin Harrington (@HarringtonKevin) October 17, 2022
Read the announcement https://t.co/qFGRfmHbHd pic.twitter.com/UznebqzK1w
Psycheceutical Bioscience, Inc. Announces Medical Advisory Board
Press Release | 10/18/2022
MIAMI, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, has announced the formation of The Psycheceutical Bioscience Medical Advisory Board.
Psycheceutical's Medical Advisory Board is comprised of highly-respected healthcare providers with exceptional experience in advancing their respective fields of medicine. They are expected to be integral in helping to guide the research and development efforts related to Psycheceutical's next-generation psychedelic dosing technology, which is being developed to provide safer, more effective therapeutics. The Psycheceutical Bioscience Medical Advisory Board's first focus will be to support the Company’s efforts to bring its innovative drug delivery technologies to market.
"Psycheceutical is at the forefront of innovation for the pharmaceutical adaptation of psychedelics, and I am proud to lead a board of well-respected and knowledgeable healthcare providers in helping Psycheceutical achieve its goal of continuously improving pharmaceutical delivery technologies and therapies for psychedelic medicine," said Dr. Julian Bailes, Principal Medical Advisor of Psycheceutical. "I am excited to work with Psycheceutical in its efforts to bring the best pharmaceutical technology to the psychedelic and mental health spaces."
The initial members of Psycheceutical's newly formed Medical Advisory Board are:
Julian E. Bailes, MD
Dr. Bailes is the Chairman of the Department of Neurosurgery, Co-Director of the Neurological Institute at NorthShore University Health System, and Clinical Professor of Neurosurgery at the University of Chicago Pritzker School of Medicine.
Dr. Bailes is a recognized leader in the field of neurosurgery and the impact of brain injury on brain function. He’s been instrumental in the understanding of the clinical evidence of Chronic Traumatic Encephalopathy (CTE). His research interests include traumatic brain injury, and his research laboratory focuses on mechanisms of injury and pharmacological therapies. He was portrayed by the actor Alec Baldwin in the movie Concussion, which referenced his groundbreaking work with TBI, PTSD, and CTE.
Dr. Bailes will apply his unique knowledge base to the specific targeting of brain conditions with psychedelic medicines.
Thomas H. Cabell, MD
Dr. Cabell is an American Board of Internal Medicine-certified cardiologist with the Centennial Heart Group at StoneCrest Medical Center, where he focuses on the importance of emotional/mental health as it relates to physical health and disease.
Following his own life-changing experience with psychedelic medicine, Dr. Cabell became passionate about increasing the safety and access to these healing compounds for as many people as possible. Dr. Cabell brings more than 20 years of invaluable cardiology and medical expertise to the Psycheceutical team.
Tony L. Strickland M.S., Ph.D., FNAN
Dr. Strickland is the founder and CEO of Nexus Clinical Solutions and the Center for Postconcussion Syndrome and PTSD Treatment. He is a board-certified neuropsychologist and a retired Associate Clinical Professor of Neurology at the UCLA David Geffen School of Medicine.
Dr. Strickland established the Center for Postconcussion Syndrome and PTSD Treatment to provide state-of-the-art treatment and prevention services to athletes, military populations, and others with brain injuries. His deep dedication to alleviating suffering led him to explore the power and promise of psychedelic medicine.
The Medical Advisory Board will function as a broadly knowledgeable and objective group of medical experts who report periodically to Psycheceutical's executive team on matters relating to the Company's initiatives. This includes identifying and discussing significant emerging medical, science, and technology trends, and monitoring the progress of Psycheceutical's drug development pipeline.
"It is an honor and privilege for Psycheceutical to form our Medical Advisory Board with such esteemed experts as Dr. Bailes, Dr. Cabell, and Dr. Strickland. We look forward to benefiting from their deep experience and professional guidance," said Chad Harman, CEO of Psycheceutical.
About Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. (OTC: BWVI), through its wholly-owned subsidiary Psycheceutical, Inc., is seeking to develop cutting-edge delivery technologies to support safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a management and advisory team with more than 100 years combined experience in development, regulatory approval processes, and commercialization across the pharmaceutical industry, Psycheceutical is on a mission to develop, improve, and commercialize cutting-edge delivery technologies that can be used across the mental health treatment spectrum while providing safe and effective delivery of psychedelic pharmaceutical medicines. Learn more at Psycheceutical.com.
Forward-Looking Statements:
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," “may,” “should,” “could,” "intend,” “estimate,” “plan,” "anticipate,” "expect,” “believe,” “potential” or “continue,” or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications
kaia.roman@psycheceutical.com
Business still here and still making it happen, generating millions in revenues and thousands of customers every week. This continues to Create opportunity. Looking forward to the next update!
$FUNN
Curious about how our technology works and acts as treatment for psychological disorders?
— Psycheceutical (@psycheceutical) October 13, 2022
Dr. Aung-Din and Dr. Tuteja are here to break down how these compounds and technologies work and benefit those using them for treatment. pic.twitter.com/V2bdnrGAYU
Busy holiday season now, closing the gap to profitability. FY23 looking good. Looking forward to the next update.
$FUNN
Absolutely not! Going to run again,
Much happening and we will hear about it soon!
$SSFT
Just a ticker change away from a whole new era. Lets go!
Today is #WorldMentalHealthDay, a time to raise awareness of mental health issues around the world and to mobilize efforts in support of mental health. Want to learn more about our work & vision for the future of mental health treatment? Visit us at https://t.co/iLZ6MTmHCC pic.twitter.com/oonsl7UQAp
— Psycheceutical (@psycheceutical) October 10, 2022
Getting set for another run but higher chance this run its never looking back! Looking forward to the next update!
Moving quickly to the holidays, busiest time of the year!
As Mental Illness Awareness Week comes to an end, be sure to follow and support @NAMICommunicate year round to provide help & educate others on the importance of #mentalhealth and wellness. #MIAW pic.twitter.com/AZtiHewA26
— Psycheceutical (@psycheceutical) October 7, 2022
Next run coming, Going to be great. Looking forward to it news on the SAIBRE contract and developments coming. Still pulling in millions in revenues in the meantime!
We close! The show is about to begin! Going to be great. Looking forward to it, news and investor roadshow rollout. Many great things happening, epic story coming quick!
Happy Friday, weekend is here and the busier season is upon us. Snakes & Lattes pulling in millions in revenues! Looking forward to the next update!
$FUNN
Lets get that update on SAIBRE! Much happening with Sona, cant wait to hear about it!
Revenues are coming back up! Still millions coming in and the gap to profitability closing. That creates opportunity!
Looking forward to the next update!
$FUNN
Original Shark from Shark Tank @HarringtonKevin and Futurist @ZappyZapolin to open #WonderlandMiami 🍄🌴
— Microdose Psychedelic Insights (@MicrodoseHQ) October 5, 2022
"I believe that psychedelic medicine is going to be a trillion-dollar industry...," said Harrington.#psychedelic #medicinehttps://t.co/k902RC8NdJ
I did. I bought a bunch at the .005 level, that was ridiculously low.
Looking forward to the next update.
$FUNN
Lets go Sonasoft!
Off the bottom lets keep it going, millions on revenues and holiday season is here. Looking forward to the next update!
Nice! Its all coming just that last bit of ticker change lets go!
picked up a few today, accumulating! Ready to run again! Looking forward to the next update.
Busy holiday season starting up. Contributing millions in revenues and closing that gap to profitability. Lets get it FY23!
Looking forward to the next update
$FUNN